chemieunternehmen.com

Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/-6378

Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led by EQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation from new US-based funds, Frazier Life Sciences and Deep Track Capital as well as all existing investors, including Andera Partners, BioMedPartners, Fund+, Bayern Kapital (with ScaleUp-Fonds Bayern), Evotec, coparion, Seventure Partners, OCCIDENT and High-Tech Gründerfonds (HTGF). Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with an indication-tailored targeting molecule and payload combination to develop novel ADCs with superior properties. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/tubulis-closes-upsized-eur128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline-6376

Evotec SE and biotech venture capital firm Claris Ventures (“Claris”) today announced an acceleration framework to streamline programmes from Claris’s portfolio companies into the clinic through Evotec’s fully integrated platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-claris-ventures-streamline-access-to-accelerate-programmes-from-clariss-portfolio-companies-into-the-clinic-6374

Tuberculosis and malaria are among the deadliest infectious diseases worldwide and are increasingly spreading, not least due to climate change. In both cases, antimicrobial resistance renders established active substances ineffective. To ensure that effective drugs are still available in the future, researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) are working together with Evotec, a leading company for drug research and development, on resistance-breaking anti-infectives based on natural products. The research project of the team led by Prof. Rolf Müller now receives 3.1 million euros in funding from the Bill & Melinda Gates Foundation. In addition, the HIPS has been accepted as a member of the renowned „Tuberculosis Drug Accelerator“. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/developing-novel-strategies-against-tuberculosis-and-malaria-6372

Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has expanded its relationship with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) serving the US Government and biopharmaceutical industry.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-expands-development-and-manufacturing-agreement-with-abl-for-broadly-neutralising-antibodies-against-hiv-6370

Evotec SE is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-invitation-to-conference-call-6368

Evotec SE today announced that the Company has joined forces with the Crohn’s & Colitis Foundation (“the Foundation”), the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease (“IBD”), which includes Crohn’s disease and ulcerative colitis.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-crohns–colitis-foundation-enter-agreement-to-advance-drug-discovery-for-novel-ibd-therapies-6366

Evotec SE today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-progress-in-strategic-neuroscience-partnership-with-bristol-myers-squibb-6364

Evotec SE and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-owkin-enter-an-ai-powered-strategic-partnership-to-accelerate-therapeutics-pipeline-in-oncology-and-ii-6362